Stewart Cole – President, Institut Pasteur, France
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Address: Institut Pasteur
25,28 rue du Docteur Roux
75724 Paris CEDEX 15 – FRANCE
,France
Tel: 33 (0)1 45 68 80 00
Web: http://www.pasteur.fr/ip/easysite/pasteur/en
Since its creation in 1887, the Institut Pasteur has become famous throughout the world as a symbol of science and french culture. For 120 years, our foundation has been contributing to the prevention and treatment of infectious diseases through research, teaching and public health initiatives.
Across the globe, thousands of researchers who have been trained or are working at Institut Pasteur share the values which form the very core of the Pasteurian community: an original scientific approach, an ongoing preoccupation with applying research to public health needs, professional ethics, a desire to care for people regardless of their background or nationality, and an outward-looking attitude, sharing knowledge and expertise with the international community. These guiding principles make the Institut Pasteur a unique institution which values exchanges and partnerships.
The Institut Pasteur enjoys an independent status and has numerous other assets, with its research laboratories, technological platforms, teaching centre and medical centre all located on one campus in the heart of Paris. It also has an international network which currently counts 30 members spread over the five continents.
With its unique setup and prestigious history, the Institut Pasteur has always stood at the forefront of innovation, adapting to the rapidly developing world of biological research and its applications, in particular in the field of biotechnology.
Nowadays, the Institut Pasteur has four priorities to carry out its activities successfully :
– to target its scientific strategy towards infectious diseases, microbiology, virology and immunology;
– to adopt an outward-looking attitude, both within France, through agreements and collaborations with its partners : CNRS (French National Scientific Research Centre), Inserm (French National Institute for Health and Medical Research), universities, hospitals, industrial partners, etc., and at international level with the development of the Réseau International des Instituts Pasteur (International Network of the Institut Pasteur or RIIP), which counts 30 institutes;
– to implement transversal research programs on ambitious themes and led by young researchers;
– to preserve the foundation’s independence, in particular through increased resources from sponsorship and donations.
These priorities, upholding the traditional tasks and values of the Institut Pasteur, place it at the cutting edge of the 21st century’s scientific and human challenges.
Scientific Research in infectious diseases, microbiology, virology and immunology
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Dr. Zoubir Harrat heads the Institut Pasteur d’Algérie (IPA), after having spent most of his career with the institution. He talks of the importance to prepare for the healthcare challenges…
Hechmi Louzir, general manager of the Institut Pasteur in Tunis (IPT), details the crucial role that the IPT plays in the development of the Tunisian health sector, his wide-ranging responsibilities…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
How would you define the Institut Pasteur’s relationship with the pharmaceutical industry and how it has evolved in recent years? Since its foundation 120 years ago, the Institut Pasteur has…
François Vorms, managing director of Canon Medical Systems France, shares the story of how the company navigated its transition from Toshiba to become a well-known player in the medical imaging…
Elie Lobel, CEO of Orange Healthcare, explains how digitalization is bringing together stakeholders from across the healthcare continuum, allowing increased information exchange and connectivity. Lobel also gives insight into the…
Eric Le Roy, director general of SNITEM (Syndicat National de l’Industrie des Technologies Médicales, The French National Association of the Medical Technologies Industry) discusses the profile of French medtech today,…
Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care…
Martine Claret of Horus Pharma – a family-owned ophthalmology pharmaceutical company established in 2003 and based in Nice – discusses the highly regulated and competitive ophthalmology market, the company’s remarkable…
Faten Hidri, VP for Higher Education & Research in the Paris Region (Ile de France), discusses the vital role of academic research and the life sciences in her region and…
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market…
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the…
Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance…
See our Cookie Privacy Policy Here
